

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of Financial status**  
**as of 31 of December 2022**

	<b>31.12.2022</b>	<b>31.12.2021</b>
	<i>BGN'000</i>	<i>BGN'000</i>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	35 267	38 071
Intangible assets	3 814	3 451
Investments in subsidiaries	19	19
Trade receivables	5 276	5 276
<b>Total non-current assets</b>	<b>44 376</b>	<b>46 817</b>
<b>Current assets</b>		
Inventories	13 493	11 342
Trade and other receivables	61 681	59 220
Current corporate income tax		40
Cash and cash equivalents	126	40
<b>Total current assets</b>	<b>75 300</b>	<b>70 642</b>
<b>Total assets</b>	<b>119 676</b>	<b>117 459</b>
<b>LIABILITIES</b>		
<b>Equity</b>		
Share capital	84 500	84 500
Reserves	12 522	12 382
Retained earnings	4 701	1 940
<b>Total</b>	<b>101 723</b>	<b>98 822</b>
<b>Non-current liabilities</b>		
Long-term loans	1 281	1 717
Deferred tax liabilities	1 030	1 030
Retirement benefit obligations	149	151
<b>Total non-current liabilities</b>	<b>2 460</b>	<b>2 898</b>
<b>Current liabilities</b>		
Trade and other liabilities	4 811	4 720
Short-term loans	9 785	9 781
Current portion of long-term loans	738	990
Current corporate income tax		125
Other tax liabilities	159	123
<b>Total current liabilities</b>	<b>15 493</b>	<b>15 739</b>
<b>Total liabilities</b>	<b>17 953</b>	<b>18 637</b>
<b>Total equity and liabilities</b>	<b>119 676</b>	<b>117 459</b>

Date of preparation: 27.01.2023

Sofia

Prepared by:.....  
 / P. Moneva /

Executive Director:.....  
 /B. Georgiev/

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of comprehensive income**  
**as of 31 of December 2022**

	<b>31.12.2022</b>	<b>31.12.2021</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenue	42 959	42 431
Other income	721	124
<b>Total income</b>	<b>43 680</b>	<b>42 555</b>
Carrying amount of goods sold	(752)	(1 105)
Changes in inventories of finished products and work in progress	1 895	1 020
Materials and services	(31 867)	(30 678)
Personnel expenses	(5 770)	(5 680)
Depreciation / amortisation expenses	(3 568)	(3 877)
Other expenses	(448)	(776)
Finance income	574	507
Finance costs	(493)	(399)
<b>Total expenses</b>	<b>(40 429)</b>	<b>(40 988)</b>
<b>Profit before taxation</b>	<b>3 251</b>	<b>1 567</b>
Corporate income tax expense	(350)	(168)
<b>Profit/Loss for the period</b>	<b>2 901</b>	<b>1 399</b>
<b>Total comprehensive income for the period</b>	<b>2 901</b>	<b>1 399</b>
Earnings per share / in BGN per 1 share /	0.03	0.02

Date of preparation: 27.01.2023

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....


/B. Georgiev/


**Tchaikapharma High Quality Medicines Inc.**  
**Interim cash flow statement**  
**as of 31 of December 2022**

	<b>31.12.2022</b>	<b>31.12.2021</b>
	<i>BGN'000</i>	<i>BGN'000</i>
<b>Cash flows from operating activities</b>		
Proceeds from sale of finished products, goods and services	33 019	33 931
Payments to suppliers of materials, goods and services	(19 645)	(22 964)
Payments to personnel	(5 432)	(5 518)
Payments of interest and dividends	(445)	(218)
Other proceeds / payments	(5 079)	(3 206)
<b>Net cash flows</b>	<b>2 418</b>	<b>2 025</b>
 <b>Cash flows from investing activities</b>		
Payments on non-current assets acquired	(1 580)	(1 573)
<b>Net cash flows</b>	<b>(1 580)</b>	<b>(1 573)</b>
 <b>Cash flows from financial activities</b>		
Proceeds from loans	247	199
Payments on loans	(248)	(201)
Payment of interest, dividends	(229)	(200)
Payments on finance lease	(522)	(459)
Payments from government donations		204
<b>Net cash flows</b>	<b>(752)</b>	<b>(457)</b>
 <b>Change in cash and cash equivalents</b>	<b>86</b>	<b>(5)</b>
Cash and cash equivalents at the beginning of the period	<b>40</b>	<b>45</b>
Cash and cash equivalents at the end of the period	<b>126</b>	<b>40</b>

Date of preparation: 27.01.2023

Sofia

Prepared by:.....  
  
 / P. Moneva /

Executive  
 Director:.....  
  
 /B. Georgiev /

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement on changes in equity**  
**as of 31 of December 2022**

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
<b>Balance as of 01.01.2021</b>	<b>82 200</b>	<b>4 088</b>	<b>7 944</b>	<b>2 904</b>	<b>97 136</b>
Profit/loss for the period				1 399	1 399
Other comprehensive income		287			287
Including from tax effect of the revaluation of property, plant and equipment		(39)			(39)
<b>Total comprehensive income</b>		<b>287</b>		<b>604</b>	<b>593</b>
Issue of shares by the owners					
Dividends accrued					
Tantimmes accrued					
Profit transferred to reserves	2 300		63	(2 363)	
<b>Total amount of income and expenses recognised during the period</b>	<b>2 300</b>		<b>63</b>	<b>(2 363)</b>	
<b>Balance as of 31.12.2021</b>	<b>84 500</b>	<b>4 375</b>	<b>8 007</b>	<b>1 940</b>	<b>98 822</b>
<b>Balance as of 01.01.2022</b>	<b>84 500</b>	<b>4 375</b>	<b>8 007</b>	<b>1 940</b>	<b>98 822</b>
Profit/loss for the period				2 901	2 901
Other comprehensive income					
<b>Total comprehensive income</b>				<b>2 901</b>	<b>2 901</b>
Issue of shares by the owners			140	(140)	
<b>Total amount of income and expenses recognised during the period</b>			<b>140</b>	<b>(140)</b>	
<b>Balance as of 31.12.2022</b>	<b>84 500</b>	<b>4 375</b>	<b>8 147</b>	<b>4 701</b>	<b>101 723</b>

Date of preparation: 27.01.2023

Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev/